ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

New Research Grant Awards

December 13, 1974

Complaints Are “Astonishingly Far From Facts,” But NCI May Be Leaving Good Science Unfunded

April 29, 1977

Hammer Goes Public With Appeal for Increased Funding

March 14, 1986

In Brief: Tim Lee Carter, Former Congressman And NCAB Chairman, Dies; Helped Write National Cancer Act

April 3, 1987

NCAB Approves Grants For Action Plan On Breast Cancer

September 22, 1995

Mammography Screening For Ages 40-49 Not Supported By Data, NIH Pane! Says

January 31, 1997